Lactobacillus acidophilus for Health & Longevity - Quick Reference Sheet

Lactobacillus acidophilus for Health & Longevity

Created on 09/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A gut bacterium sold in fermented dairy and capsules. The clearest human results are digestive: particular laboratory lines have eased irritable bowel pain and bloating, and mixtures cut loose stools during antibiotic courses. Results attach to a named line, not the species on a label. Serious infections cluster in people with catheters, suppressed immunity, or damaged valves. (Full Review)

Protocol

Standard maintenance dose
1–10 billion colony-forming units daily
The range used across trials; the largest positive irritable bowel trial used 10 billion of DDS-1.
Strain-first selection
Selection by documented strain, not by species
DDS-1 for irritable bowel; NCFM for antibiotic cover; CL1285 for hospital use.
Best time of day
With or shortly before a meal containing some fat
Food buffers stomach acid and improves live-cell survival.
Time to effect
Bowel-habit and bloating changes
1–2 weeks
Live cells appear in stool within one to two days.
Irritable bowel symptom scores
4–6 weeks
The window at which symptom scores were measured.
Lipid changes
More than 4 weeks
Needed more than four weeks to separate from placebo.

Benefits

Contraindications
  • Central venous catheter or long-term parenteral nutrition
  • Severe neutropenia (below 500 cells/µL)
  • Critical illness; predicted severe pancreatitis
  • Prosthetic valve, cardiac device, endocarditis
  • Transplant on active immunosuppression
  • Untreated HIV (CD4 below 200 cells/µL)
  • Short bowel syndrome or D-lactic acidosis
  • Premature infants below 1,500 g, unsupervised
  • Immunosuppressants (ciclosporin, tacrolimus)
  • Cytotoxic chemotherapy causing neutropenia (cyclophosphamide, docetaxel)
Key Interactions
  • Systemic antibiotics (amoxicillin, ciprofloxacin): caution
  • Proton pump inhibitors and antacids (omeprazole): monitor
  • Antimicrobial botanicals (oregano oil, berberine): caution
  • Prebiotic supplements (inulin, lactitol): additive; caution
  • Cholesterol-lowering supplements (red yeast rice, psyllium): additive; monitor
  • Other live-microbe products and faecal microbiota transplantation: caution; avoid near a planned transplant

Risk & Side Effects

  • Medium: Excess mortality in severe acute pancreatitis; bloodstream infection and endocarditis
  • Low: Delayed gut recovery after antibiotics; gas and bloating; D-lactate build-up and brain fogginess; lactose and milk-protein exposure; small weight gain
  • Speculative: Transfer of antibiotic-resistance genes; more deconjugated bile acids in the colon

Monitoring

Marker Target Why
LDL cholesterol Below 100 mg/dL; 70 if heart risk is high The one blood measure it reliably moves
Total cholesterol 150–200 mg/dL Confirms lipid direction; tracks HDL
hs-CRP Below 1.0 mg/L Tracks any inflammatory benefit
Fasting glucose 75–90 mg/dL Screens the metabolic endpoint
HbA1c Below 5.4% Confirms glucose handling over months
Faecal calprotectin Below 50 µg/g Separates symptoms from inflammation
Breath hydrogen/methane Rise under 20 ppm within 90 minutes Identifies bacterial overgrowth
IBS symptom severity Below 75 (remission range) The scale the strongest benefit used

Cadence: Symptoms at 2, 4 and 8 weeks; lipids at 8–12 weeks, then every 6–12 months; blood counts if immunity changes.

Qualitative Assessment

  • Abdominal pain frequency and worst daily intensity on a simple 0–10 scale
  • Bloating and visible distension, noted morning and evening
  • Stool form and frequency, using the Bristol Stool Form Scale
  • Urgency and incomplete-evacuation sensation
  • Mental clarity, which deteriorates rather than improves when D-lactate accumulates
  • Number of infection episodes and antibiotic courses over a season